BIO.B vs. MTD, WAT, ILMN, AVTR, RVTY, BRKR, BIO, OLK, TXG, and LAB
Should you be buying Bio-Rad Laboratories stock or one of its competitors? The main competitors of Bio-Rad Laboratories include Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), Avantor (AVTR), Revvity (RVTY), Bruker (BRKR), Bio-Rad Laboratories (BIO), Olink Holding AB (publ) (OLK), 10x Genomics (TXG), and Standard BioTools (LAB). These companies are all part of the "analytical instruments" industry.
Bio-Rad Laboratories (NYSE:BIO.B) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, community ranking, risk, dividends, earnings and valuation.
Mettler-Toledo International has higher revenue and earnings than Bio-Rad Laboratories. Bio-Rad Laboratories is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.
Bio-Rad Laboratories has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.16, meaning that its share price is 16% more volatile than the S&P 500.
Mettler-Toledo International has a consensus target price of $1,257.14, indicating a potential downside of 10.47%. Given Mettler-Toledo International's higher probable upside, analysts clearly believe Mettler-Toledo International is more favorable than Bio-Rad Laboratories.
0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 95.1% of Mettler-Toledo International shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 1.9% of Mettler-Toledo International shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Mettler-Toledo International received 241 more outperform votes than Bio-Rad Laboratories when rated by MarketBeat users. However, 57.60% of users gave Bio-Rad Laboratories an outperform vote while only 57.46% of users gave Mettler-Toledo International an outperform vote.
Mettler-Toledo International has a net margin of 20.55% compared to Bio-Rad Laboratories' net margin of -12.37%. Bio-Rad Laboratories' return on equity of 3.59% beat Mettler-Toledo International's return on equity.
In the previous week, Mettler-Toledo International had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for Mettler-Toledo International and 0 mentions for Bio-Rad Laboratories. Bio-Rad Laboratories' average media sentiment score of 1.47 beat Mettler-Toledo International's score of 1.31 indicating that Bio-Rad Laboratories is being referred to more favorably in the media.
Summary
Mettler-Toledo International beats Bio-Rad Laboratories on 13 of the 17 factors compared between the two stocks.
Get Bio-Rad Laboratories News Delivered to You Automatically
Sign up to receive the latest news and ratings for BIO.B and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BIO.B and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BIO.B vs. The Competition
Bio-Rad Laboratories Competitors List
Related Companies and Tools
